Clinic
Group Health Plan, INC.
Group Health Plan, INC. was paid $204.32M by Medicaid between Jan 2018 and Dec 2024, across 660 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 14% of everything it billed.
33Billing provider infoGROUP HEALTH PLAN, INC.
MINNEAPOLIS, MN 55407
MINNEAPOLIS, MN 55407
33aNPI1710924683assigned 06/01/2006
33bProvider typeUrgent Care Clinic/Center
28Total paid$204.32M
24GClaims6,118,276
24DCodes billed660
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Urgent Care Clinic/Center providers in Minnesota
Rank by total paid#1 of 44
Median peer was paid$996K
This provider vs. median205×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BJORKMAN, LISA controls 18+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,141,676 | $10.64M | |
| 2019 | 1,103,687 | $40.04M | |
| 2020 | 914,447 | $35.39M | |
| 2021 | 1,180,294 | $47.57M | |
| 2022 | 870,373 | $33.96M | |
| 2023 | 494,917 | $19.79M | |
| 2024incomplete | 412,882 | $16.93M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 14% | 437,342 | 381,115 | $28.79M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 12% | 497,277 | 448,478 | $23.57M |
| 99233 | Hospital visit by a doctor, follow-up day (complex)Prolong inpt eval add15 m | 7.1% | 273,373 | 55,968 | $14.41M |
| 99223 | Prolong inpt eval add15 m | 3.1% | 65,556 | 42,065 | $6.32M |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 2.4% | 57,814 | 51,535 | $4.97M |
| S0302 | Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) | 2.3% | 155,974 | 152,904 | $4.63M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.2% | 51,256 | 48,637 | $4.44M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 2.2% | 69,274 | 65,973 | $4.41M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.8% | 40,964 | 38,480 | $3.74M |
| 59400 | Routine obstetric care including antepartum care, vaginal delivery, and postpartum care | 1.7% | 3,696 | 3,436 | $3.53M |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.6% | 29,467 | 8,521 | $3.17M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.5% | 46,775 | 45,295 | $3.08M |
648 more codes
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 1.5% | 39,026 | $3.02M |
| 99232 | Hospital visit by a doctor, follow-up day | 1.4% | 87,406 | $2.88M |
| 99310 | Prolong nursin fac eval 15m | 1.4% | 46,454 | $2.81M |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 1.4% | 102,530 | $2.81M |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | 1.3% | 29,378 | $2.68M |
| T1013 | Sign language or oral interpretive services, per 15 minutes | 1.2% | 82,388 | $2.42M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 1.2% | 37,410 | $2.40M |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.2% | 34,557 | $2.37M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.1% | 40,542 | $2.32M |
| X5622 | 1.1% | 69,452 | $2.31M | |
| 99239 | Hospital discharge day management, more than 30 minutes | 1.0% | 38,473 | $2.10M |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 39,748 | $1.52M |
| 59510 | <1% | 1,476 | $1.47M | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 21,048 | $1.46M |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 108,283 | $1.42M |
| 36415 | Collection of venous blood by venipuncture | <1% | 378,692 | $1.27M |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 14,935 | $1.22M |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 16,568 | $1.21M |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 35,149 | $1.19M |
| V2020 | Frames, purchases | <1% | 37,299 | $1.18M |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 19,245 | $1.13M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 40,624 | $1.10M |
| 99205 | Prolong outpt/office vis | <1% | 10,218 | $1.08M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 33,670 | $1.06M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 33,134 | $1.05M |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 1,346 | $1.04M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 33,639 | $950K |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 23,822 | $949K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 12,292 | $874K |
| 92015 | Determination of refractive state | <1% | 70,049 | $853K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 19,345 | $826K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 50,688 | $791K |
| J0178 | Injection, aflibercept, 1 mg | <1% | 369 | $723K |
| 99385 | <1% | 8,650 | $678K | |
| 90961 | <1% | 5,466 | $659K | |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 857 | $651K |
| 99220 | <1% | 7,237 | $649K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 8,975 | $638K |
| 92340 | Fitting of spectacles, except for aphakia; monofocal | <1% | 27,114 | $632K |
| 90750 | <1% | 5,928 | $630K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 68,691 | $629K |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 9,262 | $623K |
| 92551 | <1% | 97,694 | $616K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 40,568 | $612K |
| 99188 | <1% | 73,278 | $606K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 134,894 | $559K |
| 99336 | <1% | 10,111 | $544K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 943 | $517K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 23,405 | $513K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 11,318 | $475K |
| V2103 | Spherocylinder, single vision, plano to plus or minus 4.00d sphere, .12 to 2.00d cylinder, per lens | <1% | 30,661 | $474K |
| 90651 | <1% | 17,243 | $467K | |
| 90686 | <1% | 77,839 | $465K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 6,432 | $464K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 5,039 | $441K |
| 76818 | <1% | 5,291 | $422K | |
| 80061 | Lipid panel | <1% | 33,235 | $418K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 7,261 | $417K |
| 76830 | Ultrasound, transvaginal | <1% | 5,618 | $409K |
| 96127 | <1% | 111,263 | $408K | |
| 87480 | <1% | 21,447 | $406K | |
| 87510 | <1% | 21,407 | $405K | |
| 90732 | <1% | 4,692 | $405K | |
| 87660 | <1% | 21,396 | $405K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 7,936 | $397K |
| 88307 | <1% | 3,671 | $393K | |
| 90837 | Psychotherapy session, about an hour | <1% | 5,324 | $391K |
| 86481 | <1% | 3,617 | $387K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 62,137 | $381K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,711 | $380K |
| 99384 | <1% | 4,794 | $370K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 5,415 | $368K |
| 90715 | <1% | 21,525 | $364K | |
| 99383 | <1% | 5,472 | $356K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 23,524 | $349K |
| 76801 | <1% | 4,452 | $345K | |
| 90691 | <1% | 3,762 | $343K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 2,717 | $336K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 10,082 | $321K |
| 99460 | <1% | 5,813 | $320K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 49,157 | $317K |
| 0001A | <1% | 8,173 | $308K | |
| 85027 | <1% | 53,337 | $291K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 38,863 | $291K |
| 97802 | <1% | 5,253 | $284K | |
| 87507 | <1% | 660 | $280K | |
| 91320 | <1% | 2,504 | $278K | |
| V5261 | Hearing aid, digital, binaural, bte | <1% | 157 | $276K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 6,558 | $275K |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and allowed practitioners to affirm the initial implementation of the plan of care | <1% | 14,599 | $270K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 15,627 | $264K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 619 | $263K |
| 99386 | <1% | 2,913 | $263K | |
| 0002A | <1% | 6,715 | $261K | |
| 90746 | <1% | 4,742 | $256K | |
| 90962 | <1% | 3,434 | $255K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 14,635 | $254K |
| 93793 | <1% | 33,821 | $247K | |
| 86780 | <1% | 19,702 | $241K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 12,188 | $240K |
| 17110 | <1% | 3,885 | $234K | |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 2,702 | $234K |
| 99381 | <1% | 4,303 | $232K | |
| 91322 | <1% | 1,780 | $227K | |
| 90677 | <1% | 1,990 | $220K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,450 | $215K |
| 99217 | <1% | 5,846 | $212K | |
| 82728 | <1% | 16,617 | $210K | |
| 59025 | Fetal non-stress test | <1% | 11,199 | $210K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,460 | $203K |
| 99337 | <1% | 1,571 | $199K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 24,223 | $197K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 4,076 | $196K |
| 90480 | <1% | 6,091 | $196K | |
| 88342 | <1% | 3,339 | $192K | |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | <1% | 4,341 | $192K |
| V2203 | Spherocylinder, bifocal, plano to plus or minus 4.00d sphere, .12 to 2.00d cylinder, per lens | <1% | 8,599 | $190K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,827 | $186K |
| 92060 | <1% | 4,546 | $180K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 8,233 | $172K |
| 92341 | <1% | 6,313 | $171K | |
| 76825 | <1% | 897 | $168K | |
| 99349 | <1% | 2,268 | $167K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,979 | $166K |
| 80053 | Comprehensive metabolic panel | <1% | 14,982 | $166K |
| 99397 | <1% | 1,667 | $161K | |
| 0004A | <1% | 4,884 | $154K | |
| 86803 | <1% | 11,757 | $154K | |
| 80050 | General health panel | <1% | 2,958 | $152K |
| 92134 | <1% | 5,493 | $151K | |
| 99306 | Prolong nursin fac eval 15m | <1% | 1,627 | $150K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,631 | $149K |
| 81025 | <1% | 20,347 | $147K | |
| 99382 | <1% | 2,428 | $144K | |
| 83655 | <1% | 12,825 | $142K | |
| 90717 | <1% | 1,254 | $137K | |
| 86003 | <1% | 24,790 | $136K | |
| 83970 | <1% | 3,440 | $136K | |
| 90670 | <1% | 28,873 | $133K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,798 | $133K |
| 99173 | <1% | 89,534 | $129K | |
| 99402 | <1% | 3,523 | $129K | |
| J9035 | Injection, bevacizumab, 10 mg | <1% | 1,619 | $128K |
| 99221 | <1% | 2,393 | $126K | |
| 93000 | <1% | 15,268 | $125K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 2,032 | $124K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,460 | $123K |
| 97803 | <1% | 3,143 | $122K | |
| 0071A | <1% | 2,962 | $120K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 977 | $120K |
| 82607 | <1% | 8,386 | $118K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 15,764 | $118K |
| 84466 | <1% | 8,327 | $116K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 2,520 | $115K |
| 73630 | <1% | 6,278 | $112K | |
| J7300 | Intrauterine copper contraceptive (paragard) | <1% | 170 | $108K |
| 0072A | <1% | 2,570 | $106K | |
| 31575 | <1% | 1,761 | $106K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,366 | $105K |
| 76813 | <1% | 1,362 | $105K | |
| 90734 | <1% | 14,039 | $104K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,197 | $102K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,424 | $102K |
| 58300 | <1% | 2,105 | $100K | |
| 83020 | <1% | 6,641 | $100K | |
| 95886 | <1% | 1,240 | $98K | |
| 87340 | <1% | 10,169 | $95K | |
| 0064A | <1% | 2,659 | $95K | |
| 81001 | <1% | 37,276 | $94K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 2,243 | $93K |
| 20610 | <1% | 2,591 | $93K | |
| 99350 | Prolong home eval add 15m | <1% | 992 | $92K |
| 88142 | <1% | 6,105 | $88K | |
| 82565 | <1% | 18,330 | $87K | |
| V2100 | Sphere, single vision, plano to plus or minus 4.00, per lens | <1% | 5,599 | $87K |
| 87506 | <1% | 515 | $87K | |
| G0124 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician | <1% | 3,142 | $87K |
| 84460 | <1% | 17,090 | $84K | |
| 84403 | <1% | 3,386 | $83K | |
| 69210 | <1% | 3,012 | $82K | |
| V5160 | Dispensing fee, binaural | <1% | 271 | $82K |
| 58301 | <1% | 1,412 | $80K | |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and allowed practitioners to affirm the initial implementation of the plan of care | <1% | 3,091 | $80K |
| 99219 | <1% | 1,094 | $78K | |
| 92557 | <1% | 3,368 | $77K | |
| 76820 | <1% | 2,426 | $76K | |
| S0281 | Medical home program, comprehensive care coordination and planning, maintenance of plan | <1% | 10,177 | $74K |
| 90632 | <1% | 1,635 | $73K | |
| 0011A | <1% | 2,035 | $72K | |
| 92567 | <1% | 7,762 | $71K | |
| 82570 | <1% | 14,249 | $70K | |
| 92083 | <1% | 1,685 | $70K | |
| 11981 | <1% | 1,092 | $69K | |
| 80076 | <1% | 10,921 | $68K | |
| G0008 | Administration of influenza virus vaccine | <1% | 10,271 | $68K |
| 86235 | <1% | 1,977 | $67K | |
| 85018 | <1% | 30,773 | $67K | |
| 84702 | <1% | 4,865 | $67K | |
| 88341 | <1% | 682 | $66K | |
| 73610 | <1% | 3,440 | $66K | |
| 83540 | <1% | 10,690 | $65K | |
| 85060 | <1% | 3,408 | $65K | |
| 0124A | <1% | 1,847 | $64K | |
| 0012A | <1% | 1,697 | $63K | |
| 87536 | <1% | 881 | $63K | |
| 99462 | <1% | 2,626 | $63K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 641 | $62K |
| 85610 | <1% | 20,532 | $61K | |
| 99443 | <1% | 4,916 | $61K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 1,064 | $61K |
| 0054A | <1% | 1,617 | $59K | |
| 84439 | <1% | 7,279 | $59K | |
| 90674 | <1% | 6,619 | $59K | |
| 57454 | <1% | 678 | $58K | |
| 82043 | <1% | 10,533 | $58K | |
| 90716 | <1% | 9,037 | $57K | |
| 86706 | <1% | 4,648 | $55K | |
| 84450 | <1% | 11,571 | $55K | |
| 87088 | <1% | 7,279 | $54K | |
| 84270 | <1% | 2,634 | $54K | |
| 90739 | <1% | 339 | $54K | |
| 86762 | <1% | 3,928 | $54K | |
| 90694 | <1% | 3,750 | $53K | |
| 31231 | <1% | 464 | $53K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 2,819 | $52K |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | <1% | 28 | $52K |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 3,218 | $52K |
| 82248 | <1% | 9,741 | $52K | |
| 87517 | <1% | 1,245 | $51K | |
| 36416 | <1% | 17,092 | $51K | |
| 87529 | <1% | 1,128 | $48K | |
| 82274 | <1% | 2,849 | $48K | |
| 0134A | <1% | 1,355 | $48K | |
| 87077 | <1% | 6,070 | $47K | |
| 92133 | <1% | 1,958 | $47K | |
| 90461 | <1% | 11,704 | $46K | |
| 87070 | <1% | 5,978 | $46K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 848 | $46K |
| 76536 | <1% | 626 | $45K | |
| 86140 | <1% | 9,379 | $45K | |
| 82105 | <1% | 2,864 | $44K | |
| 73562 | <1% | 1,815 | $44K | |
| 84146 | <1% | 2,414 | $44K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 825 | $44K |
| 87338 | <1% | 3,275 | $44K | |
| V2104 | Spherocylinder, single vision, plano to plus or minus 4.00d sphere, 2.12 to 4.00d cylinder, per lens | <1% | 2,981 | $44K |
| 83516 | <1% | 3,899 | $44K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,126 | $41K |
| 99226 | <1% | 657 | $41K | |
| 83735 | <1% | 6,411 | $41K | |
| 11982 | <1% | 625 | $40K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,908 | $40K |
| 99316 | <1% | 763 | $40K | |
| 94010 | <1% | 2,996 | $39K | |
| 88304 | <1% | 1,863 | $38K | |
| 86850 | <1% | 4,412 | $38K | |
| 87186 | <1% | 4,770 | $38K | |
| 73030 | <1% | 2,012 | $38K | |
| 83880 | <1% | 986 | $38K | |
| 81003 | <1% | 20,903 | $38K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,034 | $37K |
| 73564 | <1% | 1,418 | $37K | |
| 99442 | <1% | 4,508 | $37K | |
| 83001 | <1% | 2,121 | $37K | |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | <1% | 319 | $36K |
| 90675 | <1% | 98 | $36K | |
| 10060 | <1% | 497 | $35K | |
| 69209 | <1% | 3,732 | $35K | |
| 90661 | <1% | 4,440 | $34K | |
| 86480 | <1% | 1,504 | $34K | |
| V2107 | Spherocylinder, single vision, plus or minus 4.25 to plus or minus 7.00 sphere, .12 to 2.00d cylinder, per lens | <1% | 2,097 | $34K |
| V5266 | Battery for use in hearing device | <1% | 1,700 | $34K |
| 93294 | <1% | 1,515 | $34K | |
| 85049 | <1% | 8,517 | $34K | |
| 73502 | <1% | 1,245 | $33K | |
| 88141 | <1% | 1,933 | $33K | |
| 92136 | <1% | 968 | $33K | |
| 72100 | <1% | 1,536 | $33K | |
| 96161 | <1% | 21,297 | $32K | |
| 0051A | <1% | 845 | $32K | |
| 83718 | <1% | 4,385 | $32K | |
| 86160 | <1% | 2,830 | $32K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 633 | $32K |
| V5020 | Conformity evaluation | <1% | 445 | $32K |
| 90707 | <1% | 7,394 | $31K | |
| 87209 | <1% | 1,592 | $31K | |
| 84481 | <1% | 2,019 | $30K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 121 | $30K |
| 82784 | <1% | 2,923 | $29K | |
| V2200 | Sphere, bifocal, plano to plus or minus 4.00d, per lens | <1% | 1,484 | $29K |
| 99417 | Prolong home eval add 15m | <1% | 786 | $29K |
| 82947 | <1% | 8,172 | $29K | |
| 86360 | <1% | 678 | $29K | |
| 93971 | <1% | 487 | $28K | |
| 84153 | <1% | 1,680 | $28K | |
| 90653 | <1% | 342 | $27K | |
| 99201 | <1% | 1,198 | $27K | |
| 84132 | <1% | 6,491 | $27K | |
| 82746 | <1% | 1,876 | $26K | |
| 92587 | <1% | 2,143 | $26K | |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | <1% | 1,449 | $26K |
| 99285 | Emergency room visit (most serious) | <1% | 213 | $25K |
| 90473 | <1% | 1,901 | $25K | |
| 88312 | <1% | 266 | $25K | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 9,022 | $25K |
| 73110 | <1% | 1,105 | $25K | |
| 88112 | <1% | 657 | $25K | |
| 83721 | <1% | 2,675 | $25K | |
| 87522 | Neg quan hep c or qual rna | <1% | 719 | $25K |
| 90662 | <1% | 3,224 | $25K | |
| 90714 | <1% | 1,676 | $24K | |
| 74019 | <1% | 1,259 | $24K | |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 743 | $23K |
| G0659 | Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes | <1% | 640 | $23K |
| 76821 | <1% | 333 | $23K | |
| 86704 | <1% | 2,039 | $23K | |
| 86359 | <1% | 673 | $23K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 310 | $23K |
| 73140 | <1% | 1,126 | $23K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,759 | $23K |
| 92579 | <1% | 820 | $22K | |
| 77080 | <1% | 2,452 | $22K | |
| 95806 | <1% | 389 | $21K | |
| 52000 | <1% | 202 | $20K | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 7,965 | $20K |
| 92591 | <1% | 339 | $20K | |
| 84402 | <1% | 750 | $20K | |
| 99284 | Emergency room visit (serious) | <1% | 245 | $20K |
| 83690 | <1% | 3,156 | $20K | |
| 46600 | <1% | 312 | $20K | |
| 83520 | <1% | 1,513 | $20K | |
| 82465 | <1% | 4,937 | $19K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 135 | $19K |
| 93325 | <1% | 1,327 | $18K | |
| 96415 | <1% | 701 | $18K | |
| 92552 | <1% | 1,026 | $18K | |
| 92002 | <1% | 460 | $18K | |
| 82681 | <1% | 604 | $18K | |
| 95117 | <1% | 2,993 | $18K | |
| 86038 | <1% | 1,833 | $18K | |
| 11102 | <1% | 245 | $18K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 4,183 | $18K |
| 82950 | <1% | 4,113 | $17K | |
| 84295 | <1% | 4,000 | $17K | |
| 87177 | <1% | 2,246 | $17K | |
| 82670 | <1% | 680 | $17K | |
| 98941 | Chiropractic manipulative treatment; spinal, 3-4 regions | <1% | 1,086 | $17K |
| 73130 | <1% | 824 | $16K | |
| 0052A | <1% | 408 | $16K | |
| 85652 | <1% | 6,811 | $16K | |
| 86317 | <1% | 2,328 | $16K | |
| 84207 | <1% | 559 | $16K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 108 | $16K |
| 82951 | <1% | 1,317 | $16K | |
| 82627 | <1% | 734 | $15K | |
| 86618 | <1% | 1,002 | $15K | |
| 84425 | <1% | 704 | $15K | |
| 83002 | <1% | 864 | $15K | |
| 86787 | <1% | 1,283 | $15K | |
| 82550 | <1% | 2,548 | $15K | |
| 82247 | <1% | 3,303 | $15K | |
| 93976 | <1% | 137 | $14K | |
| 81329 | <1% | 119 | $14K | |
| 11900 | <1% | 511 | $14K | |
| A4627 | Spacer, bag or reservoir, with or without mask, for use with metered dose inhaler | <1% | 982 | $14K |
| 86039 | <1% | 1,324 | $14K | |
| 0082A | <1% | 417 | $14K | |
| 96160 | <1% | 8,128 | $13K | |
| 99292 | <1% | 163 | $13K | |
| 99497 | <1% | 324 | $13K | |
| 20550 | <1% | 529 | $13K | |
| 84550 | <1% | 3,169 | $13K | |
| 87481 | <1% | 348 | $13K | |
| 86696 | <1% | 669 | $13K | |
| 99177 | <1% | 1,470 | $12K | |
| 87210 | <1% | 3,820 | $12K | |
| 11104 | <1% | 111 | $12K | |
| 84156 | <1% | 3,464 | $12K | |
| 86900 | <1% | 4,164 | $12K | |
| 86901 | <1% | 4,129 | $12K | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 202 | $11K |
| 64615 | <1% | 129 | $11K | |
| 82310 | <1% | 2,265 | $11K | |
| 93351 | <1% | 240 | $11K | |
| 83013 | <1% | 148 | $11K | |
| 81401 | <1% | 113 | $11K | |
| 11200 | <1% | 226 | $10K | |
| 86225 | <1% | 898 | $10K | |
| 90713 | <1% | 2,279 | $10K | |
| 0031A | <1% | 269 | $10K | |
| 64483 | <1% | 133 | $10K | |
| 84165 | <1% | 1,006 | $10K | |
| 92556 | <1% | 535 | $10K | |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | <1% | 43 | $10K |
| 86200 | <1% | 861 | $10K | |
| 80069 | <1% | 1,174 | $10K | |
| 86708 | <1% | 905 | $10K | |
| 11750 | <1% | 105 | $10K | |
| 87493 | <1% | 399 | $10K | |
| 74018 | <1% | 549 | $9K | |
| 72050 | <1% | 356 | $9K | |
| 93227 | <1% | 691 | $9K | |
| 85730 | <1% | 1,609 | $9K | |
| 90672 | <1% | 8,047 | $9K | |
| 86431 | <1% | 1,760 | $9K | |
| 0154A | <1% | 218 | $9K | |
| 86769 | <1% | 198 | $9K | |
| 51798 | <1% | 1,321 | $9K | |
| G0009 | Administration of pneumococcal vaccine | <1% | 1,507 | $9K |
| 84703 | <1% | 1,277 | $8K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 477 | $8K |
| 86695 | <1% | 638 | $8K | |
| 95720 | <1% | 69 | $8K | |
| 87205 | <1% | 2,077 | $8K | |
| 95012 | <1% | 732 | $8K | |
| 86255 | <1% | 630 | $8K | |
| 99401 | <1% | 439 | $8K | |
| 86376 | <1% | 645 | $7K | |
| E0114 | Crutches underarm, other than wood, adjustable or fixed, pair, with pads, tips and handgrips | <1% | 284 | $7K |
| V2784 | Lens, polycarbonate or equal, any index, per lens | <1% | 1,038 | $7K |
| 87631 | <1% | 47 | $7K | |
| 90474 | <1% | 788 | $7K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,570 | $7K |
| 93016 | <1% | 588 | $7K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 61 | $7K |
| 99152 | <1% | 1,003 | $7K | |
| 76770 | <1% | 89 | $7K | |
| 99174 | <1% | 2,219 | $7K | |
| 86256 | <1% | 593 | $7K | |
| 86336 | <1% | 444 | $7K | |
| 0081A | <1% | 292 | $6K | |
| 84520 | <1% | 1,835 | $6K | |
| 99441 | <1% | 1,272 | $6K | |
| 93018 | <1% | 775 | $6K | |
| 99403 | <1% | 147 | $6K | |
| 84100 | <1% | 1,387 | $6K | |
| 94726 | <1% | 828 | $6K | |
| 64493 | <1% | 88 | $6K | |
| 95251 | <1% | 287 | $6K | |
| 58100 | <1% | 77 | $5K | |
| 76376 | <1% | 663 | $5K | |
| 93308 | <1% | 330 | $5K | |
| 93295 | <1% | 259 | $5K | |
| L0621 | Sacroiliac orthosis, flexible, provides pelvic-sacral support, reduces motion about the sacroiliac joint, includes straps, closures, may include pendulous abdomen design, prefabricated, off-the-shelf | <1% | 420 | $5K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 16 | $5K |
| 94729 | <1% | 890 | $5K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 74 | $5K |
| 82533 | <1% | 274 | $5K | |
| 84704 | <1% | 311 | $5K | |
| 84163 | <1% | 312 | $5K | |
| 80306 | <1% | 458 | $5K | |
| 11100 | <1% | 381 | $4K | |
| 95811 | <1% | 108 | $4K | |
| 85045 | <1% | 1,153 | $4K | |
| 82040 | <1% | 920 | $4K | |
| 94060 | <1% | 380 | $4K | |
| 81513 | <1% | 28 | $4K | |
| 0112A | <1% | 105 | $4K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 835 | $4K |
| 87634 | <1% | 57 | $4K | |
| 71101 | <1% | 174 | $4K | |
| 92250 | <1% | 141 | $4K | |
| 88173 | <1% | 52 | $4K | |
| 0003A | <1% | 253 | $4K | |
| 43235 | <1% | 86 | $4K | |
| 83525 | <1% | 321 | $4K | |
| 92511 | <1% | 51 | $4K | |
| 86308 | <1% | 891 | $4K | |
| 84075 | <1% | 800 | $4K | |
| 87206 | <1% | 760 | $4K | |
| 96040 | <1% | 103 | $4K | |
| 83498 | <1% | 127 | $4K | |
| 82150 | <1% | 672 | $4K | |
| 99607 | <1% | 64 | $4K | |
| 86765 | <1% | 282 | $3K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 55 | $3K |
| 73660 | <1% | 166 | $3K | |
| 99451 | <1% | 141 | $3K | |
| 17000 | <1% | 103 | $3K | |
| 99404 | <1% | 43 | $3K | |
| 86592 | <1% | 758 | $3K | |
| 99356 | <1% | 87 | $3K | |
| 93352 | <1% | 136 | $3K | |
| V2105 | Spherocylinder, single vision, plano to plus or minus 4.00d sphere, 4.25 to 6.00d cylinder, per lens | <1% | 187 | $3K |
| 99605 | <1% | 55 | $3K | |
| 83993 | <1% | 156 | $3K | |
| 0111A | <1% | 76 | $3K | |
| 0083A | <1% | 73 | $3K | |
| 84144 | <1% | 163 | $3K | |
| 86147 | <1% | 76 | $3K | |
| 82397 | <1% | 203 | $3K | |
| 99421 | <1% | 354 | $3K | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 67 | $3K |
| 86735 | <1% | 218 | $3K | |
| 0074A | <1% | 269 | $3K | |
| 84155 | <1% | 762 | $3K | |
| 72040 | <1% | 173 | $3K | |
| 73560 | <1% | 112 | $3K | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,891 | $3K |
| 95909 | <1% | 38 | $3K | |
| 58340 | <1% | 13 | $3K | |
| 11983 | <1% | 24 | $3K | |
| 99335 | <1% | 213 | $3K | |
| 87081 | <1% | 2,603 | $2K | |
| 87101 | <1% | 361 | $2K | |
| 0144A | <1% | 59 | $2K | |
| 82785 | <1% | 123 | $2K | |
| 90785 | <1% | 215 | $2K | |
| 73590 | <1% | 179 | $2K | |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 55 | $2K |
| 87563 | <1% | 57 | $2K | |
| L4360 | Walking boot, pneumatic and/or vacuum, with or without joints, with or without interface material, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | <1% | 46 | $2K |
| 92523 | <1% | 13 | $2K | |
| 92593 | <1% | 55 | $2K | |
| 85379 | <1% | 183 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,727 | $2K |
| 90710 | <1% | 6,117 | $2K | |
| 86682 | <1% | 159 | $2K | |
| 87220 | <1% | 555 | $2K | |
| 76377 | <1% | 53 | $2K | |
| 92553 | <1% | 149 | $2K | |
| 87505 | <1% | 12 | $2K | |
| 92020 | <1% | 92 | $2K | |
| 93272 | <1% | 102 | $2K | |
| 82962 | <1% | 1,224 | $2K | |
| 87184 | <1% | 204 | $2K | |
| 17250 | <1% | 39 | $2K | |
| 99406 | <1% | 138 | $1K | |
| 84112 | <1% | 30 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 110 | $1K |
| 80164 | <1% | 111 | $1K | |
| 97161 | <1% | 25 | $1K | |
| 90744 | <1% | 1,693 | $1K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 28 | $1K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 133 | $1K |
| L4350 | Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf | <1% | 43 | $1K |
| 64494 | <1% | 26 | $1K | |
| 73523 | <1% | 39 | $1K | |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 436 | $1K |
| 80074 | <1% | 25 | $1K | |
| 98940 | <1% | 220 | $1K | |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | <1% | 14 | $1K |
| L2999 | Lower extremity orthoses, not otherwise specified | <1% | 208 | $1K |
| 76514 | <1% | 154 | $1K | |
| 92285 | <1% | 76 | $1K | |
| 80051 | <1% | 151 | $1K | |
| 92550 | <1% | 67 | $1K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 153 | $1K |
| 76831 | <1% | 13 | $1K | |
| 82977 | <1% | 193 | $1K | |
| 92555 | <1% | 100 | $1K | |
| 86665 | <1% | 49 | $1K | |
| 82952 | <1% | 386 | $1K | |
| 84134 | <1% | 56 | $973.32 | |
| 76870 | <1% | 12 | $948.42 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 918 | $942.38 |
| 72110 | <1% | 40 | $938.19 | |
| 12001 | <1% | 14 | $922.92 | |
| 93280 | <1% | 42 | $863.52 | |
| 92583 | <1% | 24 | $845.23 | |
| 91200 | <1% | 136 | $828.95 | |
| 27096 | <1% | 15 | $803.87 | |
| 90723 | <1% | 22,596 | $777.50 | |
| 51702 | <1% | 16 | $774.62 | |
| 0034A | <1% | 42 | $765.00 | |
| 90647 | <1% | 21,863 | $750.20 | |
| V2108 | Spherocylinder, single vision, plus or minus 4.25d to plus or minus 7.00d sphere, 2.12 to 4.00d cylinder, per lens | <1% | 35 | $729.54 |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 12 | $711.22 |
| 20553 | <1% | 27 | $690.44 | |
| 73070 | <1% | 49 | $686.72 | |
| 72072 | <1% | 26 | $684.87 | |
| 90680 | <1% | 17,312 | $661.34 | |
| A6448 | Light compression bandage, elastic, knitted/woven, width less than three inches, per yard | <1% | 652 | $658.93 |
| 82435 | <1% | 133 | $655.56 | |
| 73090 | <1% | 28 | $649.01 | |
| 92582 | <1% | 13 | $648.48 | |
| 93321 | <1% | 151 | $603.21 | |
| L3260 | Surgical boot/shoe, each | <1% | 101 | $597.62 |
| 82610 | <1% | 38 | $596.40 | |
| 84445 | <1% | 12 | $594.77 | |
| 85670 | <1% | 91 | $575.30 | |
| V2204 | Spherocylinder, bifocal, plano to plus or minus 4.00d sphere, 2.12 to 4.00d cylinder, per lens | <1% | 36 | $558.15 |
| 92504 | <1% | 25 | $526.72 | |
| 76519 | <1% | 13 | $518.53 | |
| 96381 | <1% | 33 | $515.25 | |
| 87147 | <1% | 311 | $509.66 | |
| 92082 | <1% | 14 | $491.22 | |
| 98968 | <1% | 44 | $481.33 | |
| 84630 | <1% | 40 | $473.68 | |
| 36620 | <1% | 13 | $472.64 | |
| 86664 | <1% | 25 | $424.12 | |
| 99606 | <1% | 13 | $407.40 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 14 | $404.16 |
| 80178 | <1% | 76 | $403.98 | |
| 80177 | <1% | 27 | $393.42 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 21 | $376.33 |
| V2101 | Sphere, single vision, plus or minus 4.12 to plus or minus 7.00d, per lens | <1% | 19 | $366.70 |
| 86663 | <1% | 25 | $363.86 | |
| 82677 | <1% | 12 | $360.48 | |
| 73552 | <1% | 12 | $347.76 | |
| 95816 | <1% | 17 | $332.11 | |
| 85048 | <1% | 151 | $330.80 | |
| 73080 | <1% | 14 | $322.60 | |
| 99498 | <1% | 13 | $319.57 | |
| 90660 | <1% | 591 | $301.21 | |
| 83615 | <1% | 78 | $279.51 | |
| 90633 | <1% | 18,051 | $274.05 | |
| 92025 | <1% | 12 | $264.64 | |
| 86364 | <1% | 13 | $258.66 | |
| 86709 | <1% | 43 | $248.64 | |
| A4570 | Splint | <1% | 64 | $230.26 |
| 70355 | <1% | 26 | $221.90 | |
| 86141 | <1% | 12 | $213.00 | |
| A4565 | Slings | <1% | 74 | $212.71 |
| 88302 | <1% | 12 | $205.55 | |
| 84480 | <1% | 12 | $188.30 | |
| 84478 | <1% | 28 | $179.20 | |
| 93790 | <1% | 12 | $168.74 | |
| 85660 | <1% | 24 | $155.76 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 1,569 | $155.08 |
| 87107 | <1% | 13 | $154.08 | |
| 86707 | <1% | 12 | $148.96 | |
| 87350 | <1% | 12 | $146.66 | |
| 86580 | <1% | 46 | $142.26 | |
| 90696 | <1% | 6,593 | $119.26 | |
| 45381 | <1% | 12 | $108.70 | |
| 82340 | <1% | 13 | $80.36 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 647 | $58.04 |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 15 | $44.70 |
| G0010 | Administration of hepatitis b vaccine | <1% | 25 | $37.33 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 19 | $22.02 |
| 90700 | <1% | 6,424 | $18.73 | |
| J1071 | Injection, testosterone cypionate, 1 mg | <1% | 104 | $3.00 |
| 91319 | 0% | 329 | $0.00 | |
| 91318 | 0% | 160 | $0.00 | |
| 95910 | 0% | 13 | $0.00 | |
| 57455 | 0% | 13 | $0.00 | |
| 88738 | 0% | 34 | $0.00 | |
| 90381 | 0% | 29 | $0.00 | |
| S0280 | Medical home program, comprehensive care coordination and planning, initial plan | 0% | 27 | $0.00 |
| 99444 | 0% | 28 | $0.00 | |
| 91300 | 0% | 59 | $0.00 | |
| 90685 | 0% | 925 | $0.00 | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 0% | 165 | $0.00 |
| 91321 | 0% | 186 | $0.00 | |
| 99307 | 0% | 24 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 13 | $0.00 |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBJORKMAN, LISA (DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Group Health Plan INC. | Minneapolis, MN | $14.79M |
| Group Health Plan INC | Andover, MN | $12.93M |
| Group Health Plan INC. | Eden Prairie, MN | $11.52M |
| Group Health Plan INC | Saint Paul, MN | $5.57M |
| Group Health Plan, INC | Stillwater, MN | $3.65M |
| Group Health Plan INC | Saint Paul, MN | $3.61M |
| Group Health Plan INC | Saint Paul, MN | $1.16M |
| Physicians Neck & Back Clinics | Roseville, MN | $859K |
| Group Health Plan INC | Minneapolis, MN | $828K |
| Group Health Plan, INC. | Saint Paul, MN | $779K |
| Group Health Plan INC | Bloomington, MN | $594K |
| Lakeview Memorial Hospital Association INC | Stillwater, MN | $159K |
| Group Health Plan, INC. | Anoka, MN | $84K |
| Group Health Plan INC | Somerset, WI | $80K |
| Group Health Plan INC | Hudson, WI | $53K |
| Group Health Plan, INC | Stillwater, MN | $50K |
| Group Health Plan, INC | Maplewood, MN | $17K |
| Group Health Plan INC | Saint Paul, MN | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.